Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy

Objectives To determine whether assessment of all moderate-to-severe symptoms at baseline gives a more accurate evaluation of the treatment effect of ospemifene in vulvovaginal atrophy (VVA) than the most bothersome symptom (MBS) approach. Methods Data were pooled from two pivotal phase-III clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruyniks, N., Nappi, R. E., Castelo-Branco, C., de Villiers, T. J., Simon, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720043/
https://www.ncbi.nlm.nih.gov/pubmed/26669628
http://dx.doi.org/10.3109/13697137.2015.1113517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720043/
https://www.ncbi.nlm.nih.gov/pubmed/26669628
http://dx.doi.org/10.3109/13697137.2015.1113517

Ejemplares similares